[Adoptive immunotherapy in patients with malignant glioma].
We report preliminary results of adoptive immunotherapy in 12 patients with malignant glioma. The patients received both 1.8 to 20 X 10(8) autologous lymphokine activated killer (LAK) cells, and 8 to 16 X 10(4) units of interleukin-2. Objective regression of the tumor was observed in 8 patients. In 4 cases, the size of the tumor was remarkably reduced. No severe side effects were observed. Furthermore, LAK cells and their precursor cells were serologically studied.
D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D002648:Child; D005260:Female; D005910:Glioma / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000637:transplantation*; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
D007376:Interleukin-2